Fresenius SE & Co. KGaA

Company

Fresenius SE & Co. KGaA develops one asset, in human trials (Renalive LP in chronic kidney disease). Mostly supplement.

1
Asset
Furthest stage: Human trials; 1
Grant: 1
Trial: 0
Signals

Pipeline

1

Renalive LP
High-energy, low-protein nutritional formula designed for non-dialysis chronic kidney disease
Human trials, Supplement, chronic kidney disease, low protein dietary intake

Full company profiles: pipeline, trials, funding and people.

Subsidiaries

1

Fresenius Kabi Taiwan
1 asset, 1 trial

In the full profile

Trials1
Similar companies6